InvVax
We use a new genetics platform to develop better vaccines for flu, COVID-19, etc
Last Funded April 2024
$124,203
raised from 132 investors
Highlights
1
Huge global market for these vaccines: Universal flu - $22B; COVID-19 - $5B
2
Chance to make an enormous societal impact
3
Patented durable and universal flu vaccine
4
Major smashes: Moderna, BioNTech, Novavax: Invest in the next one!
Featured Investor
Our Team
*To our knowledge, this is the only universal flu vaccine targeting invariant sequence of influenza, but there could be, in theory, others that we do not know about.
Source: Vision Research Reports.
To our knowledge, we are the only company focused on invariance. There could be others we do not know about.
Forward-looking projections are not guaranteed.
Forward-looking projections are not guaranteed.